جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

124 مُخرَج نتائج البحث عن «Meta-analysis»

مراجعةوصول مغلق2026

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure in Children and Adolescents: A Single-Arm and Pairwise Systematic Review and Meta-Analysis with GRADE Assessment of the Evidence

Cardiology in Review

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a cornerstone of adult heart failure (HF) therapy and are increasingly prescribed off-label to children, yet pediatric outcomes have never been pooled. We searched PubMed/MEDLINE, Embase, Scopus, and Web of Science to 14 August 2026 for studies of any SGLT2 inhibitor in children or adolescents with HF and performed a single-arm meta-analysis of all exposed patients and a pairwise meta-analysis of the comparative studies with random-effects models. Nine studies contributed 599 exposed patients and 97 controls. Pooled rates were 3.8% (95% confidence interval [CI] 1.6-8.4) for mortality, 8.5% (6.2-11.5) for transplantation, 11.2% (8.2-15.1) for worsening HF, 0.2% (0.03-1.6) for ketoacidosis, 4.5% (1.2-14.9) for acute kidney injury, 3.7% (1.1-11.7) for urinary tract infection, and 4.1% (1.4-11.2) for discontinuation because of an adverse event. After initiation, left ventricular ejection fraction rose by 7.7 percentage points (3.6-11.8) and natriuretic peptide fell by 0.42 standard deviations (0.34-0.49). In the comparative synthesis (63 exposed, 97 unexposed), risk ratios were 0.80 (0.11-6.07) for mortality and 0.21 (0.03-1.68) for worsening HF; ejection fraction improved 3.34 percentage points more with SGLT2 inhibitors (0.22-6.46) whereas natriuretic peptide did not differ (standardized mean difference -0.09, -0.50 to 0.33).

SGLT2 inhibitorsheart failurepediatric heart failurechildren and adolescents
مراجعةوصول مفتوح2026

Rifaximin Versus Placebo for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (9) · e116820-e116820

Rifaximin, a minimally absorbed broad-spectrum oral antibiotic, is used to target gut dysbiosis in patients with irritable bowel syndrome (IBS).However, conflicting trial data and methodological heterogeneity necessitate an updated, rigorous synthesis of its efficacy and safety profile.We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing rifaximin with placebo in adult patients with IBS, adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines.The primary outcome was global symptom relief at the end of the treatment.Data were pooled using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment.Evidence robustness was evaluated using prediction intervals (PI), Trial Sequential Analysis (TSA), trim-and-fill algorithms for publication bias, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.Nine RCTs (yielding 10 randomized comparisons due to one trial's a priori stratification by small intestinal bacterial overgrowth status) were included in this review.For the primary outcome (eight comparisons, N=2,056), rifaximin significantly improved global symptom relief compared to placebo (RR 1.54, 95% CI 1.13 to 2.11; p=0.014), corresponding to a number needed to treat for benefit (NNTB) of 6.However, statistical heterogeneity was substantial (I 2 =59.5%), and the 95% PI crossed the line of no effect (0.89-2.67).The primary effect lost statistical significance upon the exclusion of high-risk-of-bias trials (RR 1.47, 95% CI 0.95-2.27)and after adjusting for publication bias using the trim-and-fill method (RR 1.37, 95% CI 0.93-2.01).The TSA indicated that the accrued information size remained inconclusive for a conservative 15% relative benefit.Rifaximin demonstrated no statistically detectable difference in adverse events compared to placebo, though this is accompanied by considerable uncertainty (Peto OR 0.89 (95% CI 0.65-1.22)).Rifaximin demonstrates a modest overall benefit for global IBS symptoms and an excellent safety profile; however, the certainty of evidence is very low.The apparent efficacy is highly fragile, driven largely by industry-funded trials, undermined by publication bias, and characterized by wide prediction intervals.Biomarker-guided stratification, such as testing for small intestinal bacterial overgrowth (SIBO), may be required to optimize patient selection in future independent trials.

rifaximinirritable bowel syndromeplacebo comparisonantibiotic therapy
مراجعةوصول مفتوح2026

The Impact of Preexisting Cardiac Implantable Electronic Devices on the Safety of Transcatheter Tricuspid Valve Interventions: A Systematic Review and Meta-Analysis

Journal of Cardiovascular Development and Disease · مجلد 13 (10) · 478-478

Background: Tricuspid regurgitation (TR) increases mortality but remains undertreated due to high surgical risks. Transcatheter tricuspid valve interventions (TTVI) offer safer alternatives, improving functional status and quality of life. However, many candidates for TTVI have trans-tricuspid CIED leads that may interfere with procedural imaging and device deployment and may be exposed to dislodgement, entrapment, or jailing. Evidence regarding both clinical outcomes and postprocedural CIED function in this population remains limited. Existing trial evidence for this population is scarce, requiring further safety analysis. To our knowledge, this is the first meta-analysis to address the comparative risk of complications and residual TR in patients with vs. without CIEDs. Methods: We searched for relevant articles up to March 2026 from PubMed, Scopus, Cochrane Library, and Web of Science. Two independent reviewers extracted data from the selected studies, including baseline information, outcomes, comorbidities, hospitalization metrics, TR severity, and complications. All data analyses were performed using R version 4.4.1. Results: Ten studies comprising 5415 patients were included. Nine comparative studies contributed to the quantitative synthesis, whereas one single-arm study contributed only to the narrative synthesis of CIED-specific mechanical and electrical outcomes. In patients undergoing TTVI, across two studies, patients with CIEDs had a nominally lower risk of single-leaflet device attachment (RR 0.34, 95% CI 0.12–0.94; nominal p = 0.037); however, this exploratory finding should be considered hypothesis-generating. However, no statistically significant differences were observed between groups for cardiovascular death (RR 1.30, p = 0.815), device embolization (RR 1.62, p = 0.666), device malposition (RR 1.10, p = 0.909), stroke (RR 0.52, p = 0.335), hospitalization for heart failure (RR 1.02, p = 0.931), in-hospital mortality (RR 1.02, p = 0.959), major adverse events (RR 0.74, p = 0.635), major bleeding (RR 0.70, p = 0.187), or residual tricuspid regurgitation of mild (RR 0.98, p = 0.686) or moderate severity (RR 1.01, p = 0.646). CIED-specific outcomes were reported heterogeneously. Lead function was generally preserved after T-TEER in carefully selected patients, whereas studies of TTVR with jailed leads reported lead failure or malfunction ranging from 5.8% to 21% in individual cohorts. Conclusions: Among the comparative outcomes available for quantitative pooling, no statistically significant differences were detected between patients with and without CIEDs for most procedural and postprocedural outcomes. However, CIED-specific risks differed according to the intervention. Lead function was generally preserved after T-TEER in carefully selected patients, whereas lead jailing during TTVR was associated with clinically relevant lead malfunction in some cohorts. Therefore, the absence of significant differences in pooled clinical outcomes should not be interpreted as evidence that TTVI does not affect CIED function.

transcatheter tricuspid valve interventiontricuspid regurgitationcardiac implantable electronic devicesdevice embolization
مراجعةوصول مفتوح2026

Efficacy and Safety of Vernakalant for Cardioversion of Atrial Fibrillation and Flutter: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine · مجلد 15 (19) · 7406-7406

Background/Objectives: Vernakalant is an atrial-selective antiarrhythmic used for rapid pharmacological cardioversion of recent-onset atrial fibrillation. This systematic review and meta-analysis evaluated the efficacy and safety of vernakalant compared with placebo, active antiarrhythmic therapy, and electrical cardioversion. Methods: PubMed, Embase, Google Scholar, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to August 2026. Randomized clinical trials, clinical trials, and comparative observational studies evaluating vernakalant in adults with atrial fibrillation or atrial flutter were included. Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using the Mantel–Haenszel random-effects model in RevMan 5.4. Results: Twenty controlled studies involving 4523 patients were included, of whom 2349 received vernakalant and 2174 received control therapy. Vernakalant significantly increased successful conversion to sinus rhythm compared with all controls (1234/2244 (55%) vs. 991/2147 (46.2%); RR = 1.63; 95% CI [1.34, 1.99]; p < 0.00001). The effect was strongest versus placebo (RR = 5.33; 95% CI [1.95, 14.60]; p = 0.001) and remained significant versus procainamide (111/178 (62.3%) vs. 83/172 (48.2%); RR = 1.29; 95% CI [1.07, 1.57]; p = 0.009) and flecainide (209/280 vs. 209/330 (63.3%); RR = 1.18; 95% CI [1.05, 1.33]; p = 0.007), but non-significant against amiodarone, propafenone, ibutilide, or electrical cardioversion. Safety outcomes did not differ significantly between groups, including all-cause mortality (RR = 1.23), drug discontinuation (RR = 0.98), serious adverse events (RR = 0.87), ventricular tachycardia (RR = 0.68), bradycardia (RR = 1.31), and hypotension (RR = 0.80). Conclusions: Vernakalant was associated with higher rates of conversion to sinus rhythm, while no statistically significant differences were observed in major safety outcomes. These findings support its use as a pharmacological option for rapid rhythm restoration in appropriately selected patients.

vernakalantatrial fibrillationatrial flutterpharmacological cardioversion
مراجعةوصول مفتوح2026

Post-acne Erythema: A Systematic Review of Randomized Controlled Trials on the Comparative Efficacy and Safety of Interventions Across Clinical, Instrumental, and Patient-Reported Outcomes

Cureus · مجلد 18 (9) · e116495-e116495

Post-acne erythema (PAE) is a persistent acne sequela without an established standard treatment. This systematic review evaluated the comparative efficacy and safety of interventions tested in randomized trials. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through August 1, 2026. Randomized parallel-group and split-face trials reporting erythema outcomes were eligible. Risk of bias was assessed with the Cochrane Risk of Bias 2 (RoB 2) tool. Heterogeneity precluded meta-analysis, and available findings were synthesized narratively. Nine trials involving 301 participants contributed 11 pairwise comparisons. Against untreated or blank controls, favorable effects were reported for picosecond alexandrite laser, narrow-spectrum vascular intense pulsed light (IPL), and non-cross-linked hyaluronic acid mesotherapy. A 577-nm semiconductor laser showed interim instrumental benefit, but blinded assessors found no final between-side difference. In active-treatment and add-on comparisons, narrow-spectrum IPL was favored over broad-spectrum IPL, neodymium-doped yttrium aluminum garnet (Nd) laser added to low-dose isotretinoin was favored over isotretinoin alone, and 577-nm pro-yellow laser was favored over topical brimonidine. Botulinum toxin type A was favored over broadband light at the earliest assessment only. Fractional laser and pulsed dye laser did not differ significantly, while delicate pulsed light and Q-switched 1064-nm Nd laser showed no sustained difference at the final assessment. Adverse events were mild and transient, although pigmentation and blistering occurred with one broad-spectrum IPL protocol. Five trials had some concerns, and four had high overall risk of bias. Trials suggested potential benefits, but small samples, heterogeneity, short follow-up, and reporting limitations precluded identification of a preferred treatment. Larger, prospectively registered trials using blinded assessment and standardized outcomes are needed.

intense pulsed lightNd:YAG laserisotretinoinbrimonidine
مراجعةوصول مفتوح2026

Comparative Efficacy and Safety of Non-Cryotherapy Treatments Versus Cryotherapy for Plantar Warts: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Clinical Medicine · مجلد 15 (18) · 7071-7071

Background/Objectives: To systematically evaluate and compare the clinical efficacy and safety of non-cryotherapy modalities versus standard liquid nitrogen cryotherapy for the treatment of plantar warts, while exploring the influence of specific cryotherapy procedural parameters and intervention-related subgroup characteristics on treatment outcomes. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted according to PRISMA guidelines. We searched four major databases from inception until 1 July 2026. The primary outcome was complete clearance. Secondary outcomes included partial clearance, recurrence, and treatment-related adverse events. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated using random-effects models. Results: Thirty-one RCTs involving 2313 patients were included. No statistically significant difference was detected between non-cryotherapy modalities and cryotherapy in complete clearance rates (RR = 1.09, 95% CI: 0.98–1.20; p = 0.10; I2 = 0.00%) or recurrence outcomes (RR = 0.90, 95% CI: 0.56–1.44; p = 0.66). Partial clearance significantly favored cryotherapy (RR = 0.65, 95% CI: 0.44–0.95; p = 0.03), particularly in subgroup analyses using two freeze–thaw cycles and treatment intervals of every two weeks. Regarding safety, topical therapies demonstrated significantly lower erythema rates than cryotherapy, while no statistically significant differences were observed in blistering, scarring, or secondary bacterial infection. Conclusions: No statistically significant difference was detected between non-cryotherapy modalities and cryotherapy regarding complete clearance or recurrence of plantar warts. Cryotherapy may offer better partial clearance under optimized treatment parameters, whereas topical therapies may be better tolerated in selected patients.

plantar wartscryotherapyliquid nitrogentopical treatment
مراجعةوصول مفتوح2026

Effects of Transcranial Direct Current Stimulation Versus Sham Stimulation on Brain-Derived Neurotrophic Factor and Clinical Outcomes: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine · مجلد 15 (18) · 6992-6992

Purpose: This study aimed to evaluate the effects of active transcranial direct current stimulation (tDCS) compared with sham stimulation on circulating brain-derived neurotrophic factor (BDNF), pain-related outcomes, working memory, and inflammatory and neuroplasticity biomarkers. Methods: PubMed/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov were searched from inception to May 2026. Randomized and controlled clinical trials comparing active with sham tDCS in adults were included. The primary outcome was post-treatment BDNF concentration. Secondary outcomes included pain intensity, pain catastrophizing, pain-related disability and functional interference, working memory, and circulating inflammatory or neuroplasticity biomarkers. Risk of bias was assessed using the revised Cochrane risk-of-bias tool. Mean differences (MDs) with 95% confidence intervals (CIs) were pooled using random-effects models. Serum and plasma BDNF were analyzed separately. Results: Twenty-one studies were included in the systematic review, of which 15 contributed to at least one quantitative synthesis and 12 study comparisons contributed to the primary BDNF analyses. Active tDCS did not significantly affect serum BDNF (MD = −0.01 [−0.15, 0.13], p = 0.890) or plasma BDNF (MD = 0.02 [−0.25, 0.29], p = 0.870) compared with sham stimulation. In contrast, active tDCS was associated with lower pain intensity (MD = −1.79 [−2.34, −1.23], p < 0.00001). No statistically significant difference was observed in the PCS total score or in the helplessness, magnification, or rumination subscales, although the point estimates generally favored active tDCS. For pain-related disability and functional interference, active tDCS was associated with lower PCP:S total scores and lower emotional interference, whereas no significant differences were observed for interference with daily activities or pain frequency. No significant differences were observed for working memory, interleukins, tumor necrosis factor-alpha, glial cell line-derived neurotrophic factor, interleukin-18, or soluble tumor necrosis factor receptors. Substantial heterogeneity was present in several pain-related and inflammatory biomarker analyses. Conclusions: Active tDCS was not associated with consistent differences in circulating serum or plasma BDNF or in the assessed peripheral inflammatory and neuroplasticity biomarkers compared with sham stimulation; however, these null peripheral findings should not be interpreted as evidence of absent central neuroplastic effects, because circulating measures may not adequately capture localized or transient biological changes within the central nervous system. Active tDCS was associated with improvements in some pain-related outcomes; however, the limited number of studies, substantial heterogeneity, and low certainty of the available evidence preclude firm conclusions regarding its clinical effectiveness for pain management.

transcranial direct current stimulationsham stimulationbrain-derived neurotrophic factorpain intensity
مراجعةوصول مفتوح2026

Oteseconazole for acute and recurrent vulvovaginal candidiasis: A systematic review, meta-analysis, and trial sequential analysis of randomized trials

Journal of International Medical Research · مجلد 54 (9) · 3000605261476919-3000605261476919

ObjectivesVulvovaginal candidiasis and its recurrent vulvovaginal candidiasis form place a significant burden on women worldwide. However, treatment options remain limited. Oteseconazole, a first-in-class tetrazole CYP51 inhibitor that received Food and Drug Administration approval for recurrent vulvovaginal candidiasis in 2022, has not yet had its comparative efficacy against fluconazole in acute vulvovaginal candidiasis systematically synthesized. In addition, the full scope of evidence for its maintenance use has not been formally synthesized. Using a dual-Population-Intervention-Comparator-Outcome (PICO) framework, this systematic review and meta-analysis aimed to: (a) evaluate whether oteseconazole provides superior efficacy to fluconazole in acute vulvovaginal candidiasis; (b) comprehensively synthesize maintenance efficacy and safety outcomes in recurrent vulvovaginal candidiasis; and (c) assess the certainty and sufficiency of the available evidence using Grading of Recommendations Assessment, Development, and Evaluation and trial sequential analysis.MethodsThis systematic review and meta-analysis was prospectively registered with PROSPERO (registration number: CRD420261331936). A systematic search of PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov was conducted without date or language restrictions. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. Meta-analyses were performed using random-effects models with restricted maximum likelihood estimation and Hartung-Knapp-Sidik-Jonkman correction.ResultsA total of five unique randomized controlled trials (six PICO-level inclusions) were included, enrolling 596 participants across PICO 1 and 1090 across PICO 2. In acute vulvovaginal candidiasis (PICO 1, two trials, n = 361), oteseconazole was associated with a significantly higher therapeutic cure rate (composite clinical and mycological cure) at day 28 than fluconazole (risk ratio = 1.39, 95% confidence interval: 1.13 to 1.71; p = 0.002). Significant improvements were also observed in clinical cure at day 28 (risk ratio = 1.28, 95% confidence interval: 1.09 to 1.51; p = 0.003) and mycological cure at both day 14 (risk ratio = 1.24, 95% confidence interval: 1.09 to 1.41; p = 0.001) and day 28 (risk ratio = 1.38, 95% confidence interval: 1.20 to 1.58; p < 0.001). In recurrent vulvovaginal candidiasis prevention (PICO 2, four trials, n = 959), oteseconazole significantly reduced culture-confirmed recurrence at weeks 48-50 (risk ratio = 0.13, 95% confidence interval: 0.09 to 0.19) and week 24 (risk ratio = 0.10, 95% confidence interval: 0.07 to 0.15) and substantially prolonged the time to first recurrence (hazard ratio = 0.09, 95% confidence interval: 0.05 to 0.14), all with zero heterogeneity. Furthermore, trial sequential analysis confirmed that the cumulative evidence surpassed the required information size for both recurrence time points. Safety outcomes were comparable between groups in both settings.ConclusionsIn patients with recurrent vulvovaginal candidiasis, oteseconazole demonstrated favorable outcomes by significantly reducing recurrent infections while maintaining a comparable safety profile, supporting its use as a maintenance regimen. However, the evidence supporting its role in acute vulvovaginal candidiasis remains limited.

oteseconazolerecurrent vulvovaginal candidiasisfluconazoleCYP51 inhibitors
مراجعةوصول مفتوح2026

Neuromuscular Electrical Stimulation for Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials Evaluating Pain, Disability, Muscle Strength, and Functional Performance

Orthopedic Reviews · مجلد 18 · 168252-168252

Background: Neuromuscular electrical stimulation (NMES) is widely used in the rehabilitation of knee osteoarthritis (KOA) to improve quadriceps activation and counteract arthrogenic muscle inhibition. However, randomized controlled trials (RCTs) have reported inconsistent findings, and the overall clinical effectiveness of NMES across key patient outcomes remains uncertain. Objective: To evaluate the effects of NMES, administered alone or in combination with exercise, on pain, self-reported disability, quadriceps muscle strength, and functional performance in adults with KOA, and to explore whether treatment effects differ according to comparator intervention. Methods: A systematic review and meta-analysis of RCTs was conducted according to PRISMA 2020. PubMed/MEDLINE, Embase, Scopus, Web of Science, and CENTRAL were searched from inception to April 20, 2026. Random-effects meta-analyses were performed using restricted maximum likelihood estimation. Prespecified subgroup and sensitivity analyses were undertaken, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Eight unique RCTs (10 publications) were included. Overall, NMES did not significantly improve pain, self-reported disability, quadriceps strength, or six-minute walk distance compared with pooled comparator interventions. A significant improvement was observed for Timed Up and Go performance, although this estimate was largely driven by a single trial. Prespecified subgroup analyses demonstrated that treatment effects differed according to comparator intervention. NMES combined with exercise resulted in greater pain reduction than exercise alone, whereas no consistent advantage was observed when NMES was compared with alternative conservative interventions. Most trials were judged to have low risk of bias or some concerns. Conclusions: NMES does not appear to provide consistent clinical benefits across all rehabilitation settings for KOA. Rather, its effectiveness depends on the therapeutic context in which it is delivered, with the greatest benefit observed when used as an adjunct to structured exercise rather than as a stand-alone intervention. Larger, methodologically rigorous RCTs using standardized stimulation protocols are required to define the patients most likely to benefit.

neuromuscular electrical stimulationknee osteoarthritisquadriceps strengtharthrogenic muscle inhibition
مراجعةوصول مفتوح2026

Comparative Effectiveness of Nonoperative Treatments for Acute Anterior Epistaxis in Emergency and Otolaryngology Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (8) · e115154-e115154

Acute anterior epistaxis is frequently managed with multiple nonoperative interventions, but comparative evidence regarding their effectiveness remains uncertain. This systematic review and meta-analysis evaluated the effectiveness and safety of nonoperative treatments for acute anterior epistaxis in emergency and otolaryngology settings. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through 3 July 2026 for randomized controlled trials (RCTs) comparing nonoperative hemostatic interventions in adults with acute anterior epistaxis. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool, and random-effects meta-analysis was performed when sufficient clinical comparability was present. Nine RCTs including 1,124 participants were identified, with three trials contributing to quantitative synthesis. Topical tranexamic acid reduced rebleeding within 24 hours compared with matched vehicle controls (RR, 0.39; 95% CI, 0.17-0.89), with an absolute risk reduction of 19.1 percentage points. However, topical tranexamic acid was not associated with a significant reduction in further hemostatic intervention (RR, 0.59; 95% CI, 0.22-1.59). Other nonoperative strategies showed variable effects across heterogeneous outcomes. Overall, topical tranexamic acid may reduce early rebleeding in acute anterior epistaxis, but evidence regarding broader clinical outcomes remains limited by the small number of comparable trials, heterogeneous protocols, and inconsistent outcome definitions. Further high-quality randomized trials with standardized outcomes are required to clarify the optimal role of these interventions.

conservative treatmentepistaxis managementemergency department careotolaryngology practice
مقالوصول مفتوح2026

Evaluating the efficacy and safety of melatonin for sleep onset insomnia in children aged 6–12: a systematic review and meta-analysis

BMC Pediatrics

Abstract Background Melatonin is an endogenous hormone that regulates the body’s sleep-wake cycles. Due to several clinical trials, it is currently used as an exogenous supplement in pediatric patients who suffer from sleep-onset insomnia (SOI). Consequently, this systematic review and meta-analysis aimed to assess the evidence for the clinical efficacy of melatonin for SOI in children aged 6–12. Methods This systematic review and meta-analysis evaluated the efficacy and safety of Melatonin for sleep-onset insomnia in children aged 6–12 by conducting literature searches in PubMed (97), Google Scholar (111), OVID (33), and Web of Science (156) databases. We performed statistical tests using RevMan for meta-analysis. Heterogeneity was evaluated using the I2 statistic. To maintain the validity of the studies, each included study was assessed by the Cochrane Collaboration Risk of Bias (ROB) tool. The outcomes investigated were sleep onset time (SOT), sleep onset latency (SOL), total sleep time (TST), all-cause dropout rates, and adverse-event dropout rates. Results Three hundred ninety-eight records were identified, and 10 randomized clinical trials met the inclusion criteria. The results demonstrated that melatonin treatment group was associated with an earlier sleep onset time compared with placebo with a mean difference (MD) of -0.48 h (approximately 29 min earlier) (95% confidence interval [CI]: -0.93 to -0.02 h, p = 0.04). The heterogeneity between studies was moderate (I2 = 63%). On the other hand, it was noted that there has been noticed there was a remarkable reduction in sleep onset latency with melatonin compared to placebo, with an MD of -0.38 (95% CI: -0.57 to -0.20, p < 0.0001), with high heterogeneity (I2 = 82%). Conclusion Our study confirmed that melatonin has a marked effect regarding Sleep-onset insomnia in childhood. Therefore, we found there was a statistical and clinical improvement in sleep parameters such as sleep onset time (SOT) and total sleep time (TST) which demonstrated the safety and efficacy of melatonin. However, long-term efficacy and safety need to be addressed, especially in the pediatric population.

melatoninsleep onset insomniapediatric insomniachildren
مراجعةمفتوح (مستودع)2026

Preoperative risk factors for adverse outcomes following total knee arthroplasty: a systematic review and meta-analysis

Annals of Middle Eastern Medicine · مجلد 2 (3) · 302-311

This systematic review and meta-analysis evaluated preoperative patient factors associated with adverse outcomes after primary total knee arthroplasty (TKA). PubMed and Crossref were searched from 2010 to 2025 according to PRISMA guidance, and the protocol was registered in PROSPERO (CRD420261297849). Eligible studies included adults undergoing primary TKA and reported diabetes mellitus, hypertension, obesity, morbid obesity, or sex in relation to readmission, revision surgery, or deep infection. Random-effects generic inverse variance meta-analyses were performed using odds ratios from adjusted models when available; unadjusted or calculated estimates were used only when adjusted estimates were unavailable. Twelve cohort studies including 1,586,680 patients were included. Diabetes mellitus was associated with higher odds of readmission (OR 1.17, 95% CI 1.05-1.30) and revision surgery (OR 1.17, 95% CI 1.03-1.32). Morbid obesity (BMI ≥40 kg/m²) was associated with readmission, revision surgery, and deep infection. Male sex was associated with readmission and revision surgery, while non-morbid obesity and hypertension were not consistently associated with adverse outcomes. These findings support preoperative risk stratification and optimization for diabetes and morbid obesity before elective TKA. Interpretation should remain cautious because included studies were observational and heterogeneity was substantial in several analyses.

total knee arthroplastypreoperative risk factorsadverse outcomesdiabetes mellitus
ملخص مؤتمروصول مفتوح2026

Diagnostic Accuracy of Modalities For Acute Heart Failure In Emergency Settings. A Systematic Review and Diagnostic Accuracy Meta-Analysis

Saudi Journal of Emergency Medicine · مجلد 7 (1S) · 91-91

Background: Acute heart failure diagnosis in emergency departments remains challenging despite multiple available diagnostic modalities. Current emergency evaluations rely variably on clinical assessment, biomarkers, and ultrasound techniques; however, their comparative diagnostic accuracy remains inadequately compared in previous studies. This systematic review and meta-analysis aim to evaluate the diagnostic accuracy of four categories of diagnostic approaches: Clinical Assessment, Biomarker Assessment, Basic Ultrasound Assessment, and Advanced Ultrasound Assessment for diagnosing acute heart failure in emergency settings. Methods: We conducted a literature review across PubMed/MEDLINE, Scopus, Google Scholar, Cochrane Library, Google Scholar, and Web of Science up to December 2024. Studies investigating the diagnostic modalities for acute heart failure in emergency settings with sufficient data to construct 2×2 contingency tables were included. Two independent reviewers performed screening, data extraction, and quality assessment using QUADAS-2. Diagnostic accuracy was synthesized using a bivariate random-effects model. Summary receiver operating characteristic (SROC) curves, pooled sensitivity, specificity, and area under the curve (AUC) were calculated with 95% confidence intervals (CI). Heterogeneity was assessed using I² statistics and publication bias with Deeks' funnel plot. Results: Thirty-three studies including a total of 17 participants to 1,586 participants met the inclusion criteria. Clinical Assessment demonstrated moderate diagnostic performance (AUC=0.591) with limited sensitivity (0.500, 95% CI: 0.484-0.515) but high specificity (0.858, 95% CI: 0.830-0.886). Biomarker Assessment showed excellent performance (AUC=0.906) with high sensitivity (0.874, 95% CI: 0.872-0.875) and good specificity (0.781, 95% CI: 0.778-0.783). Basic Ultrasound Assessment had moderate performance (AUC=0.750) with low sensitivity (0.349, 95% CI: 0.303-0.395) but high specificity (0.889, 95% CI: 0.874-0.904). Advanced Ultrasound Assessment demonstrated excellent performance (AUC=0.892) with good sensitivity (0.713, 95% CI: 0.705-0.720) and very high specificity (0.903, 95% CI: 0.900-0.905). All modalities showed remarkably consistent performance across studies (I²=0%). Conclusion: Biomarker Assessment provides the highest overall diagnostic accuracy for acute heart failure in emergency settings, while Advanced Ultrasound Assessment offers the optimal balance between sensitivity and specificity when equipment and expertise are available. Clinical Assessment alone has limitations for detecting acute heart failure but remains useful for exclusion. Our findings highly recommend adapting a multimodal diagnostic approach integrating biomarkers and advanced ultrasound techniques whenever possible for optimal diagnostic accuracy in emergency settings.

acute heart failureemergency diagnosisdiagnostic accuracyclinical evaluation
مراجعةوصول مفتوح2026

Comparison Between High-Flow Nasal Cannula (HFNC) Therapy and Noninvasive Ventilation (NIV) in Children With Bronchiolitis-Associated Acute Respiratory Failure: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (8) · e114308-e114308

The optimal noninvasive respiratory support for infants and children with severe viral bronchiolitis remains unclear. While continuous positive airway pressure (CPAP) has traditionally been considered the gold standard, high-flow nasal cannula (HFNC) therapy is a better-tolerated alternative. This systematic review and meta-analysis aimed to evaluate the comparative efficacy and safety of HFNC versus noninvasive ventilation (NIV) in pediatric patients with bronchiolitis-associated acute respiratory failure. We searched major electronic databases through June 2026. We included randomized controlled trials (RCTs) and observational cohorts comparing HFNC with NIV (CPAP/bilevel positive airway pressure (BiPAP)). The primary outcomes were treatment failure, as defined by the individual studies, and endotracheal intubation. Data were synthesized using random-effects models, and heterogeneity was explored via subgroup analysis and meta-regression. Eleven studies (seven RCTs and four observational studies) comprising 7,574 patients were included. There was no statistically significant difference in the overall risk of treatment failure between HFNC and NIV (RR 1.99, 95% CI 0.65-6.10); however, study design was a significant moderator (p = 0.0019). Observational studies reported significantly higher failure rates with HFNC (RR 7.78), whereas RCTs showed no significant difference (RR 1.11). There were no significant differences in endotracheal intubation rates (RR 0.75, 95% CI 0.51-1.09) or pediatric intensive care unit length of stay (MD -0.16 days, 95% CI -0.79 to 0.47) between the groups. HFNC demonstrated a trend toward fewer local adverse events, such as nasal/skin trauma (RR 0.30, 95% CI 0.06-1.52), than did NIV. The certainty of evidence according to GRADE was low for all outcomes. HFNC showed no significant differences from NIV in critical clinical endpoints, including intubation rates and intensive care duration. Differences in treatment failure rates appeared to be influenced by study design, highlighting potential confounding by indication in observational data. Given its improved tolerability and trend toward reduced mucosal trauma, HFNC may represent a viable first-line noninvasive intervention for pediatric bronchiolitis.

high-flow nasal cannulanon-invasive ventilationpediatric bronchiolitisacute respiratory failure
مراجعةوصول مفتوح2026

Clinical Value of Scapular-Targeted Rehabilitation Within the Rotator Cuff Care Continuum: A Systematic Review and Meta-analysis of Conservative and Postoperative Evidence

Orthopedic Reviews · مجلد 18 · 165083-165083

Background: Scapular-targeted rehabilitation is increasingly incorporated into the management of rotator cuff-related shoulder disorders; however, its clinical value across both conservative and postoperative stages of care remains uncertain. Objective: To evaluate the effectiveness of scapular-targeted rehabilitation on pain, disability, and shoulder function across the rotator cuff care continuum. Methods: A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through May 2026. Eligible studies included adults with rotator cuff-related shoulder pain, subacromial pain syndrome, subacromial impingement syndrome, scapular dyskinesis-associated shoulder disorders, or patients undergoing rehabilitation following rotator cuff repair. Randomized controlled trials were included in quantitative synthesis. Random-effects models were used to pool standardized mean differences (SMDs) or mean differences (MDs) with 95% confidence intervals (CIs). Results: Nine studies met the inclusion criteria, comprising seven randomized controlled trials, one propensity score-matched study, and one single-group pre-post study. Meta-analysis demonstrated that scapular-targeted rehabilitation significantly reduced pain compared with control interventions (SMD -0.88, 95% CI -1.71 to -0.06; I²=84.8%) and significantly improved shoulder function measured by the Constant-Murley Score (MD 6.94, 95% CI 0.37 to 13.52; I²=85.7%). Disability outcomes favored scapular-targeted rehabilitation but did not reach statistical significance (SMD -0.47, 95% CI -1.05 to 0.11; I²=72.8%). Postoperative studies generally reported favorable effects on pain, function, and range of motion, although evidence was insufficient for quantitative synthesis. Conclusions: Scapular-targeted rehabilitation appears to be a useful adjunct within comprehensive rotator cuff rehabilitation, with evidence supporting improvements in pain and shoulder function. Evidence for disability reduction and postoperative effectiveness remains inconclusive, warranting further high-quality trials across the rotator cuff care continuum.

rotator cuff diseaserotator cuff repairshoulder impingement syndromesubacromial pain syndrome